Dibenz(b,f)azepine → 9-[(2,4-Diaminothieno[2,3-d]pyrimidin-5-yl)methyl]dibenz[b,f]azepine
反応式
NC1N=C(N)C2C(CN(C3C=CC=CC=3)C3C=CC=CC=3)=CSC=2N=1.[NH2:26][C:27]1[N:28]=[C:29]([NH2:37])[C:30]2[C:35]([CH3:36])=[CH:34][S:33][C:31]=2[N:32]=1.[CH:38]1[C:48]2[CH:47]=[CH:46][C:45]3[CH:49]=[CH:50][CH:51]=[CH:52][C:44]=3[NH:43][C:42]=2[CH:41]=[CH:40][CH:39]=1>>[NH2:26][C:27]1[N:28]=[C:29]([NH2:37])[C:30]2[C:35]([CH2:36][C:49]3[C:45]4[CH:46]=[CH:47][C:48]5[CH:38]=[CH:39][CH:40]=[CH:41][C:42]=5[NH:43][C:44]=4[CH:52]=[CH:51][CH:50]=3)=[CH:34][S:33][C:31]=2[N:32]=1参加物
4
実験手順
9-[(2,4-Diaminothieno[2,3-d]pyrimidin-5-yl)methyl]dibenz[b,f]azepine (Formula I: Ar=2,4-diaminothieno[2,3-d]pyrimidin-5-yl; W=CH2; X=N; Z=CH═CH; m=n=0) is prepared similarly to N-[(2,4-diaminothieno[2,3-d]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 2,4-diamino-5-methylthieno[2,3-d]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and dibenz[b,f]azepine (154 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.